How Long Does Abiraterone — Take to Work?

PSA often begins to decline within four to eight weeks of starting abiraterone, though the timing varies. What matters more than the exact week is the direction of the trend across multiple tests. A single early reading is not enough to draw conclusions — your oncologist will look at the pattern at your first review, typically in the six-to-eight-week range.

A small PSA rise in the first weeks does not always mean the treatment is failing. A brief early rise before a sustained fall — sometimes called a PSA flare — can occur, and it is one reason your team watches the trend across several blood tests rather than reacting to a single result. If PSA continues to rise clearly over two to three months, that is a different concern, and your oncologist will address it at your scheduled review or sooner if needed.

Imaging is typically repeated at around three months, in line with NCCN and ESMO guidance. Scans done earlier are often not useful because tumour changes on CT and bone scans take longer to appear than PSA changes. If new symptoms arise before three months — bone pain in a new location, for example — your team may scan sooner. Tell your oncologist about any new symptom rather than waiting for a scheduled appointment.

Symptoms are an unreliable guide to response, especially early on. Abiraterone itself can cause fatigue, joint pain and mild swelling, which can feel like a worsening even when PSA is falling. Pain from bone metastases sometimes increases temporarily before settling. PSA and imaging give your team a more reliable picture than symptoms alone, which is why the monitoring schedule matters even when you feel no different from one visit to the next.

If PSA rises persistently and scans show progression after a period of response, the cancer has developed resistance to abiraterone. This is expected to happen eventually for many people on long-term treatment. It does not mean all options are gone. Your oncologist will review what comes next based on your specific situation — the options depend on prior treatments, your general fitness, and other factors your team will assess at that point.

The duration varies and cannot be predicted in advance. Some people remain on abiraterone for a year or more before any sign of resistance; others respond for a shorter period. ASCO guidance does not set a fixed treatment duration — abiraterone continues for as long as it is controlling the disease and you are tolerating it well. Your oncologist will review this at each follow-up rather than committing to a fixed endpoint from the start.